Structure and function of hormone receptors and their crosstalk with growth factor receptors;Budowa i funkcja receptorów hormonalnych oraz mechanizm ich współdziałania z receptorami dla czynników wzrostu

Wspolczesna Onkologia

Volumn 14, Issue 6, 2010, Pages 347-354

  Dȩbska, Sylwia ^a   Potemski, Piotr ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Coregulator; Estrogen receptor; HER2; Membrane initiated steroid signaling

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GROWTH FACTOR RECEPTOR; HORMONE RECEPTOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER HORMONE THERAPY; CANCER RESISTANCE; HORMONE RESISTANCE; HUMAN; METASTASIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; TREATMENT RESPONSE;

EID: 78651362955     PISSN: 14282526     EISSN: 14282526     Source Type: Journal    
DOI: 10.5114/wo.2010.19149     Document Type: Article

References (43)

1. Creighton CJ, Massarweh S, Huang S, et al. Development of resistance to targeted therapies transforms the clinically-associated molecular profile subtype of breast tumor xenografts. Cancer Res 2008; 68: 7493-501.
2. Cui X, Schiff R, Arpino G, Osborne CK, Lee AV. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol 2005; 23: 7721-35. (Pubitemid 46291836)
3. Masri S, Phung S, Wang X, Wu X, Yuan YC, Wagman L, Chen S. Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen- resistant, and long-term estrogen-deprived cells reveals a role for estrogen receptor. Cancer Res 2008; 68: 4910-8.
4. Ellis MJ, Tao Y, Young O i wsp. Estrogen-independent proliferation is present in estrogen-receptor her2-positive primary breast cancer after neoadjuvant letrozole. J Clin Oncol 2006; 24: 3019-25. (Pubitemid 46638935)
5. Creighton CJ, Massarweh S, Huang S, et al. Development of resistance to targeted therapies transforms the clinically-associated molecular profile subtype of breast tumor xenografts. Cancer Res 2008; 68: 7493-501.
6. Arpino G, Wiechmann L, Osborne CK, Schiff R. Crosstalk between the estrogen receptor and the her tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocrine Reviews 2008; 29: 217-33. (Pubitemid 351519691)
7. Kurokawa H, Lenferink AE, Simpson JF, Pisacane PI, Sliwkowski MX, Forbes JT, Arteaga CL. Inhibition of HER2/neu (erbB-2) and mitogen- activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res 2000; 60: 5887-94.
8. Johnston SR, Leary A, Martin LA, Smith IE, Dowsett M. Enhancing endocrine response with novel targeted therapies. why have the clinical trials to date failed to deliver on the preclinical promise? Cancer 2008; 112: 3.
9. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: ten years of targeted anti-her-2 therapy and personalized medicine. The Oncologist 2009; 14: 320-68.
10. Dahabreh IJ, Linardou H, Siannis F, Fountzilas G, Murray S. Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials. The Oncologist 2008; 13: 620-30. (Pubitemid 351904907)
11. Zhao C, Dahlman-Wright K, Gustafsson JA. Estrogen receptor beta: an overview and update. NRS 2008; 10: 1-10.
12. Flouriot G, Brand H, Denger S, Metivier R, Kos M, Reid G, Sonntag- Bruck V, Gannon F. Identification of a new isoform of the human estrogen receptor-alfa (hER-α) that is encoded by distinct transcripts and is able to repress hER-α activation function 1. The EMBO Journal 2000; 19: 4688-700.
13. Morani A, Warner M, Gustafsson JA. Biological functions and clinical implications of oestrogen receptors alfa and beta in epithelial tissues. J Intern Med 2008; 264: 128-42. (Pubitemid 351962577)
14. http://www.bio.cmu.edu/Courses/BiochemMols/ER/ERIntro.html
15. Fleming FJ, Hill AD, McDermott EW, O'Higgins NJ, Young LS. Differential recruitment of coregulator proteins steroid receptor coactivator- 1 and silencing mediator for retinoid and thyroid receptors to the estrogen receptor-estrogen response element by estradiol and 4-hydroxytamoxifen in human breast cancer. J Clin Endocrinol Metab 2004; 89: 375-83.
16. Chang EC, Frasor J, Komm B, Katzenellenbogen BS. Impact of estrogen receptor on gene networks regulated by estrogen receptor in breast cancer cells. Endocrinology 2006; 147: 4831-42. (Pubitemid 44402189)
17. Hall JM, McDonnell DP. The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERa transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 1999; 140: 5566-78.
18. Stoica GE, Franke TF, Moroni M, et al. Effect of estradiol on estrogen receptor-a gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathway. Oncogene 2003; 22: 7998-8011. (Pubitemid 37175864)
19. Berry M, Metzger M, Chambon P. Role of the two activating domains of the estrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. The EMBO Journal 1990; 9: 2811-8. (Pubitemid 20278739)
20. Morani A, Warner M, Gustafsson JA. Biological functions and clinical implications of oestrogen receptors alfa and beta in epithelial tissues. J Int Med 2008; 264: 128-42. (Pubitemid 351962577)
21. Bai Y, Gigue're V. Isoform-selective interactions between estrogen receptors and steroid receptor coactivators promoted by estradiol and ErbB-2 signaling in living cells. Mol Endocrinol 2003; 17: 589-99.
22. Klinge CM, Jernigan SC, Mattingly KA, Risinger KE, Zhang J. Estrogen response elementdependent regulation of transcriptional activation of estrogen receptors and by coactivators and corepressors. J Mol Endocrinol 2004; 33: 387-10. (Pubitemid 39429565)
23. Heldring N, Pike A, Andersson S, et al. Estrogen Receptors: how do they signal and what are their targets. Physiol Rev 2007; 87: 905-31. (Pubitemid 47084672)
24. Massarweh S, Osborne CK, Creighton CJ, et al. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res 2008; 68: 826-33. (Pubitemid 351206760)
25. Massarweh S, Schiff R. Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities. Clin Cancer Res 2007; 13: 1950-4. (Pubitemid 46649859)
26. Massarweh S, Schiff R. Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk. Endocrine-Related Cancer 2006; 13: S15-S24. (Pubitemid 46219245)
27. Song RX, Barnes CJ, ZhangZ, Bao Y, Kumar R, Santen RJ. The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor to the plasma membrane. PNAS 2004; 101: 2076-81. (Pubitemid 38229017)
28. Dowsett M. Membrane ER in endocrine resistance In lab and the clinic: should we be convinced?http://www.abstracts2view.com/ sabcs09/view.php?nu= SABCS09L-3815&terms=
29. De Vivo I, Hankinson SE, Colditz GA, Hunter DJ. A functional polymorphism in the progesterone receptor gene is associated with an increase in breast cancer risk. Cancer Res 2003; 63: 5236-8. (Pubitemid 37139835)
30. De Vivo I, Hankinson SE, Colditz GA, Hunter DJ. The progesterone receptor Val660→Leu polymorphism and breast cancer risk. Breast Cancer Res 2004; 6: R636-9.
31. Huggins GS, Wong JY, Hankinson SE, De Vivo I. GATA5 activation of the progesterone receptor gene promoter in breast cancer cells is influenced by the +331G/A polymorphism. Cancer Res 2006; 66: 1384-90. (Pubitemid 43259918)
32. Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, Elledge RM. Estrogen receptor - positive, progesterone receptor - negative breast cancer: association with growth factor receptor expression and tamoxifen Resistance. J Natl Cancer Inst 2005; 97: 1254-61.
33. Rakha EA, El-Sayed M, Green AR, et al. Biologic and clinical characteristics of breast cancer with single hormone receptor - positive phenotype. J Clin Oncol 2007; 25: 4772-8.
34. Ravdin PM, Green S, Dorr TM, et al. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J Clin Oncol 1992; 10: 1284-91.
35. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004; 96: 926-35.
36. Britton DJ, Hutcheson IR, Knowlden JM, Barrow D, Giles M, McClelland RA, Gee JM, Nicholson RI. Bidirectional cross talk between ERa and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Res Treat 2006; 96: 131-46.
37. Yamashita H, Nishio M, Toyama T, Sugiura H, Kondo N, Kobayashi S, Fujii Y, Iwase H. Low phosphorylation of estrogen receptor alfa (ERa) serine 118 and high phosphorylation of ERa serine 167 improve survival in ER-positive breast cancer. Endocr Relat Cancer 2008; 15: 755-63.
38. Atanaskova N, Keshamouni VG, Krueger JS, Schwartz JA, Miller F, Reddy KB. MAP kinase/estrogen receptor cross-talk enhances estrogen- mediated signaling and tumor growth but does not confer tamoxifen resistance. Oncogene 2002; 21: 4000-8.
39. Stoica GE, Franke TF, Wellstein A, et al. Estradiol rapidly activates Akt via the ErbB2 signaling pathway. Mol Endocrinol 2003; 17: 818-30.
40. Stoica GE, Franke TF, Wellstein A, et al. Heregulin-b1 regulates the estrogen receptor-a gene expression and activity via the ErbB2/PI 3-K/Akt pathway. Oncogene 2003; 22: 2073-87.
41. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H. The phosphatidylinositol 3-Kinase/AKT-mediated activation of estrogen receptor alfa. A new model for anti-estrogen resistance. J Biol Chem 2001; 276: 9817-24.
42. Farach-Carson MC, Davis PJ. Steroid hormone interactions with target cells: cross talk between membrane and nuclear pathways. J Pharmacol Exp Ther 2003; 307: 839-45.
43. Bai Y, Giguere V. Isoform-selective interactions between estrogen receptors and steroid receptor coactivators promoted by estradiol and ErbB-2 signaling in living cells. Mol Endocrinol 2003; 17: 589-99.